GnRH therapy to improve cognition in individuals with Down syndrome
Official title: Effect of Pulsatile GnRH Therapy on Cognition in Down Syndrome: Randomized Placebo Control Study
Run by Centre Hospitalier Universitaire Vaudois · NCT04390646 · Data updated 2026-11-12
This study is testing if a new hormone treatment can help improve thinking skills and smell in adults with Down syndrome who are at risk for early Alzheimer's disease.
Quick facts
| Phase | Phase2; Phase3 |
|---|---|
| Study type | Interventional |
| Ages | 16 Years to 50 Years |
| Sex | All |
| Enrollment | 56 (estimated) |
| Sponsor | Centre Hospitalier Universitaire Vaudois Academic / other |
| Locations | 1 site (Lausanne, Canton of Vaud) |
| Status | Recruiting |
| Started | August 27, 2020 |
| Main results expected | December 2028 |
| Study ends | December 2028 |
| Registry record updated | February 12, 2024 |
| Trial ID | NCT04390646 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults diagnosed with Down syndrome who are able to communicate and consent to participate.
✕Probably not a fit
Patients with acute illnesses, chronic substance abuse issues, or those taking certain hormonal medications may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial investigates the effects of GnRH therapy on cognitive decline and olfactory disorders in adults with Down syndrome. The study aims to evaluate whether pulsatile administration of GnRH can enhance cognitive function and olfactory abilities in this population, who are at increased risk for early-onset Alzheimer's disease. Participants will receive either GnRH or a placebo, and their cognitive and olfactory functions will be assessed throughout the trial. The study targets individuals diagnosed with trisomy 21 who can provide verbal consent and follow study procedures.
Why it matters
Potential benefit: If successful, this therapy could provide a novel treatment option to improve cognitive and olfactory functions in adults with Down syndrome.
How similar studies have gone: While there is limited research on GnRH therapy specifically for Down syndrome, similar approaches targeting cognitive decline in other populations have shown promise.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of trisomy 21 * Verbal expression (ability to follow the procedures of the study) * Consent to a non-hormonal contraception during the whole duration of the study For women: intra-uterine device with copper, a prior tubal ligation or condoms for the partner For men: condoms or vasectomy Exclusion Criteria: * Acute illness (clinical or biochemical findings suggesting acute illness/hospitalization) * Chronic alcohol abuse, illicit drug use, anabolic steroid abuse, psychotropic drugs reported by caregivers * Taking medication that modifies hormones: spironolactone, ketoconazole, anticoagulants, corticosteroids, ACTH hormone, psychotropics, including antidepressants, antipsychotics and anticonvulsants. * Known pituitary adenoma and other hormone-dependent tumours * Participation in another clinical study * Intention to become a parent during the course of the study * Females: ovarian cysts, non-hypothalamic anovulation (i.e. polycystic ovary syndrome), pregnancy or lactation * Males: hematocrit \> 54% * Contraindications for MRI (e.g. pacemaker, metal clips,etc) * Participant or his/her legal representative do not want to be informed in case of incidental findings
Where it's running
-
Centre Hospitalier Universitaire Vaudois (CHUV)
Lausanne, Canton of Vaud, Switzerland Recruiting
Study contacts
- Principal investigator: Nelly Pitteloud, MD — Endocrinology, Metabolism, Diabetology (CHUV)
- Study coordinator: Pulse-UP study
- Email: pulseup@chuv.ch
- Phone: +41 21 314 06 25
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
China HEAD: a large community study on healthy aging and dementia
This study tests whether collecting health, imaging, and biospecimen data from adults in China can help predict who will develop Alzheimer’s disease and related dementias.
-
Kinematic analysis of hand and arm movement in kids with Down syndrome, CP and healthy children
This study tests how well an instrumented Box and Block Test and motion tracking can measure upper-limb movement in healthy kids and those with pyramidal hemisyndrome or Down syndrome.
-
Can citicoline help prevent cognitive decline after delirium in older adults with hip fracture?
This study tests whether taking citicoline for 6 months after discharge helps prevent cognitive decline in adults 65 and older who had delirium during hospitalization for hip fracture.
-
Sensory integration to help balance and movement in kids with Down syndrome
Aimed at seeing if adding sensory integration to physical therapy helps improve gross motor skills and balance in children with Down syndrome.
-
See if cognitive impairment is common in older adults admitted for non-neurological rehab
This study tests how often cognitive impairment appears in patients aged 45 and older who are in non-neurological rehab units after hospitalization.
-
Collaboration for Down Syndrome Progress (CDP) in people with Down syndrome
A long-term study following people with Down syndrome of all ages to see how health and everyday life change over time.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.